HBIO Harvard Bioscience (HBIO) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001123494
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter
HBIO filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by BroadOak Income Fund, L.P., filed 2026-03-23, for 15.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Harvard Bioscience insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for HARVARD BIOSCIENCE INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 47.6% of the 21,000 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DENELSKY STEPHEN J bought about $48.7K of HBIO on Mar 17, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 16, 2026.
- The trade is 26.5% of the 32,000 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Snider William bought about $41.1K of HBIO on Mar 17, 2026; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 53.2% of the 23,525 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Snider William bought about $62.5K of HBIO on Mar 16, 2026, the largest insider purchase at the company since 2023; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.8% of the 105,000 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Duke John D bought about $25.1K of HBIO on Mar 16, 2026, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 28.6% of the 17,500 shares held after it.
- 3 other insiders bought within 30 days.
- 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Frost Mark T bought about $25.0K of HBIO on Mar 16, 2026, the largest insider purchase at the company since 2024; 3 other insiders bought within 30 days and 8 funds added in the latest 13F quarter.26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 88% of Medical Devices
Revenue
-8.1% year over year
below 86% of Medical Devices
Margin
-65.5% net margin
below 72% of Medical Devices
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-26) · 2.6 days to cover · settled 2026-09-30
below 72% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HBIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+108.0%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HBIO: institutional holders (13F)
13F holdings, latest reported quarter
310,861 sh
$1.9M
182,992 sh
$1.1M
169,625 sh
$1.0M
143,082 sh
$880.0K
122,810 sh
$755.3K
Congress trades in HBIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
BroadOak Income Fund, L.P.
Activist 13D · 2026-03-23
15.34%
BroadOak Fund VI, L.P.
Activist 13D · 2026-03-23
0.33%
BroadOak Capital Partners, LLC
Activist 13D · 2026-03-23
15.57%
William Snider
Activist 13D · 2026-03-23
15.97%
HBIO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HBIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Gabelli Global Mini Mites Fund
$24.6K position · as of 2026-06-30
0.1%
ACUITAS US MICROCAP FUND
$82.3K position · as of 2026-06-30
0.1%
Dimensional US Sustainability Core 1 ETF
$11.6K position · as of 2026-07-31
0.0%
LVIP Dimensional U.S. Core Equity 2 Fund
$3.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$163.3K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$258.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr Green
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$2.3M
-$2.0M
$602.6K
-70%
n/a
2023
$2.4M
$7.2M
$571.3K
-24%
n/a
2022
$2.3M
-$3.7M
$495.3K
-61%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HBIO financials
Revenue growth
-8.1%
XBRL, annual
Net margin
-65.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$87.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HBIO
| FY Dec 2025 | $86.5M |
| FY Dec 2024 | $94.1M |
| FY Dec 2023 | $112.2M |
| FY Dec 2022 | $113.3M |
| FY Dec 2021 | $118.9M |
| Jun 2026 | $22.7M |
| Mar 2026 | $20.8M |
| Dec 2025 | $23.7M |
| Sep 2025 | $20.6M |
| Jun 2025 | $20.4M |
| Mar 2025 | $21.8M |
| Dec 2024 | $24.6M |
| Sep 2024 | $22.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-11.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HBIO
| FY Dec 2025 | -65.5% |
| FY Dec 2024 | -13.2% |
| FY Dec 2023 | -3.0% |
| FY Dec 2022 | -8.4% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | -12.8% |
| Mar 2026 | -16.5% |
| Dec 2025 | -12.0% |
| Sep 2025 | -6.0% |
| Jun 2025 | -11.2% |
| Mar 2025 | -231.2% |
| Dec 2024 | +0.1% |
| Sep 2024 | -21.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$1.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HBIO
| FY Dec 2025 | $5.5M |
| FY Dec 2024 | -$1.2M |
| FY Dec 2023 | $12.2M |
| FY Dec 2022 | -$438.0K |
| FY Dec 2021 | $67.0K |
| Jun 2026 | -$363.0K |
| Mar 2026 | -$1.1M |
| Dec 2025 | -$545.0K |
| Sep 2025 | $877.0K |
| Jun 2025 | $2.7M |
| Mar 2025 | $2.5M |
| Dec 2024 | $1.4M |
| Sep 2024 | -$1.7M |
At each fiscal year end
Single quarter
Debt to equity
4.94x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity HBIO
| FY Dec 2025 | 2.61x |
| FY Dec 2024 | 0.58x |
| FY Dec 2023 | 0.50x |
| FY Dec 2022 | 0.65x |
| FY Dec 2021 | 0.58x |
| Jun 2026 | 4.94x |
| Mar 2026 | 3.60x |
| Dec 2025 | 2.61x |
| Sep 2025 | 2.41x |
| Jun 2025 | 2.22x |
| Mar 2025 | 2.45x |
| Dec 2024 | 0.58x |
| Sep 2024 | 0.59x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.02x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt HBIO
| FY Dec 2025 | 0.19x |
| FY Dec 2024 | 0.04x |
| FY Dec 2023 | 0.38x |
| FY Dec 2022 | 0.02x |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.09x |
| Dec 2025 | 0.19x |
| Sep 2025 | 0.25x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.04x |
| Sep 2024 | 0.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-89.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HBIO
| FY Dec 2025 | -147.1% |
| FY Dec 2024 | -18.2% |
| FY Dec 2023 | -4.7% |
| FY Dec 2022 | -12.2% |
| FY Dec 2021 | -0.4% |
| Jun 2026 | -89.9% |
| Mar 2026 | -78.6% |
| Dec 2025 | -147.1% |
| Sep 2025 | -135.6% |
| Jun 2025 | -138.4% |
| Mar 2025 | -138.8% |
| Dec 2024 | -18.2% |
| Sep 2024 | -20.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-13.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HBIO
| FY Dec 2025 | -54.9% |
| FY Dec 2024 | -9.4% |
| FY Dec 2023 | -2.4% |
| FY Dec 2022 | -6.2% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | -13.3% |
| Mar 2026 | -12.4% |
| Dec 2025 | -54.9% |
| Sep 2025 | -51.5% |
| Jun 2025 | -54.9% |
| Mar 2025 | -54.5% |
| Dec 2024 | -9.4% |
| Sep 2024 | -10.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital HBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HBIO
| FY Dec 2025 | -74.9% |
| FY Dec 2024 | -6.8% |
| FY Dec 2023 | +1.6% |
| FY Dec 2022 | -5.4% |
| FY Dec 2021 | +1.5% |
| Jun 2026 | -0.6% |
| Mar 2026 | -0.2% |
| Dec 2025 | -74.9% |
| Sep 2025 | -76.1% |
| Jun 2025 | -79.8% |
| Mar 2025 | -81.4% |
| Dec 2024 | -6.8% |
| Sep 2024 | -5.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$68.1M
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value HBIO
| FY Dec 2025 | $325.9M |
| FY Dec 2024 | $953.2M |
| FY Dec 2023 | $2.3B |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $2.9B |
| Jun 2026 | $57.9M |
| Mar 2026 | $246.9M |
| Dec 2025 | $325.9M |
| Sep 2025 | $223.1M |
| Jun 2025 | $222.0M |
| Mar 2025 | $282.1M |
| Dec 2024 | $953.2M |
| Sep 2024 | $1.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield HBIO
| FY Dec 2025 | +1.8% |
| FY Dec 2024 | -0.1% |
| FY Dec 2023 | +0.5% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | +0.0% |
| Jun 2026 | -4.0% |
| Mar 2026 | +0.9% |
| Dec 2025 | +1.8% |
| Sep 2025 | +3.8% |
| Jun 2025 | +2.5% |
| Mar 2025 | +0.2% |
| Dec 2024 | -0.1% |
| Sep 2024 | +0.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $86.5M | $94.1M | $112.2M | $113.3M |
| Gross profit | $49.9M | $54.8M | $66.1M | $60.8M |
| Operating income | -$48.6M | -$6.2M | $1.9M | -$6.9M |
| Net income | -$56.7M | -$12.4M | -$3.4M | -$9.5M |
| EPS (diluted) | -1.28 | -0.28 | -0.08 | -0.23 |
| Operating cash flow | $6.7M | $1.4M | $14.0M | $1.2M |
| Cash | $8.6M | $4.1M | $4.3M | $4.5M |
| Long-term debt | $35.9M | $0 | $30.7M | $43.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
HBIO Stock Sonar score 5/7 axes
Find similar shapesCompareHBIO ranks highest on risk and compliance (68th percentile) and profitability (49th), and lowest on institutional and government (12th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
